glycogen storage disease

(redirected from type IV)
Also found in: Dictionary, Thesaurus, Medical, Legal.
Related to type IV: Type IV collagen

glycogen storage disease

[′glī·kə·jən ′stȯr·ij di‚zēz]
References in periodicals archive ?
CA-MRSA strains carry SCCmec type IV or V whereas the majority of HAMRSA strains carry SCCmec type I II or III.
In liver fibrosis, basement membrane forms in the perisinusoidal space and the amount of type IV collagen, a major element in the bloodstream, rises as the condition progresses.
As type IV secretion can distribute genetic material between bacteria, notably antibiotic resistance genes, the mechanism is directly responsible for the spread of antibiotic resistance in hospital settings.
Finally, Type IV portable sleep monitors have at least three channels.
A Spanish hospital experienced a decrease in gentamicin-resistant MRSA isolates (from 97% in 1998 to 20% in 2002) and a simultaneous increase in MRSA isolates carrying the SCCmec type IV cassette (from 0% prevalence in 2000 to 23% prevalence in 2002) (15).
Type IV cell-mediated allergies, the most common immune system reaction to latex, affect 82 percent of individuals allergic to rubber products.
Type IV President Andrew Kessel said the company has developed the first new therapy for warts in several decades.
Type IV glycogen storage disease (type IV GSD), also known as Andersen disease or amylopectinosis, is a rare autosomal-recessive disorder caused by the deficiency of glycogen branching enzyme.
TYPE IV PFD - A throwable device such as life rings and buoyant seat cushions.
In humans, an important CBS on the collagen type IV molecule has been characterized and it is located in the Gly-X-Y triple-helical domain.
In light of this finding, it is presumed that these cysts usually arise from the second branchial arch, and they are classified as type IV cysts according to Proctor's classification (table 2).
BioStratum Incorporated (Research Triangle Park, IL; 919-572-6515) announced the issuance of United States Patent 5,856,184 to the University of Kansas Medical Center (Kansas City, KS) on type IV collagen-derived anti-angiogenesis agents.